Quantcast
Home > Quotes > ABEO
ABEO

Abeona Therapeutics Inc. Common Stock (ABEO) Quote & Summary Data

$5.14
*  
0.23
4.28%
Get ABEO Alerts
*Delayed - data as of Jun. 18, 2019 13:15 ET  -  Find a broker to begin trading ABEO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ABEO Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 5.13 / $ 5.14
1 Year Target
24.5
Today's High / Low
$ 5.60 / $ 5.06
Share Volume
589,842
50 Day Avg. Daily Volume
438,134
Previous Close
$ 5.37
52 Week High / Low
$ 17.25 / $ 5.02
Market Cap
252,692,922
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.97

Intraday Chart

Shares Traded

Share Volume:
589,842
50 Day Avg. Daily Volume:
438,134

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.34

Trading Range

The current last sale of $5.14 is 2.39% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.60 $ 17.25
 Low: $ 5.06 $ 5.02

Company Description (as filed with the SEC)

Abeona Therapeutics Inc. (together with our subsidiaries, "we," "our," "Abeona" or the "Company"), a Delaware corporation, is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Our lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa ("RDEB"), ABO-102, an adeno-associated virus ("AAV")-based gene therapy for Sanfilippo syndrome type A ("MPS IIIA"), and ABO-101 an AAV-based gene therapy for Sanfilippo syndrome type B ("MPS IIIB"). We also are developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases. In addition, we are developing next generation AAV-based gene therapy though our novel AIM(TM) vector platform programs.  ... More ...  



Risk Grade

Where does ABEO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.56
Open Date:
Jun. 18, 2019
Close Price:
$ 5.37
Close Date:
Jun. 17, 2019


Consensus Recommendation

Analyst Info